Patient-Centered Management of Dyslipidemia: Part 1
National Lipid AssociationPublished: March 26, 2015
- Key Points
- Risk Assessment
- Treatment Recommendations
- Algorithms
- Model of Steps in Lifestyle Therapies
- Progression of Atherogenic-Cholesterol-Lowering Drug Therapy
- Tables
- Criteria for Classification of ASCVD
- Major Risk Factors for ASCVD
- Risk Calculators
- Criteria for ASCVD Risk Assessment, Treatment Goals for Atherogenic Cholesterol, and Levels at Which to Consider Drug Therapy
- High or Very High-Risk Patient Groups
- Sequential Steps in ASCVD Risk Assessment
- Classifications of Cholesterol and Triglyceride Levels
- Drugs That May Elevate LDL-C or Triglyceride Concentrations
- Risk Indicators (Other Than Major ASCVD Risk Factors) That Might be Considered for Risk Refinement
- Diet Characteristics and Diseases/Disorders/Altered Metabolic States That May Elevate LDL-C and/or Triglyceride Concentrations
- Criteria for Clinical Identification of the Metabolic Syndrome
- Treatment Goals for Non-HDL-C, LDL-C, and Apo B
- The intensity of Statin Therapy
- Apheresis
- Available drugs and Their Effects on Lipid Metabolism
- Agents for Homozygous Familial Hypercholesterolemia
You rely on Guideline Central for transparency
Guideline Central and select third party use “cookies” on this website to enhance the user experience.
This technology helps us gather statistical and analytical information to optimize the relevant content for you.
The user also has the option to opt-out which may have an effect on the browsing experience.